Merck and Ridgeback Biotherapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the refusal of the marketing authorization for lagevrio for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union. Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck shares positioned for further upside, says JPMorgan
- Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940
- Merck opens enrollment in new Phase 3 trials of islatravir/doravirine combo
- Wolfe upgrades Merck with pipeline ‘big enough to matter’
- Merck upgraded to Outperform from Peer Perform at Wolfe Research
